Tiziana Life Sciences chief medical officer Matthew Davis joins Proactive's Natalie Stoberman to share the latest results from its intranasal foralumab study that's been published in Proceedings of the National Academy of Sciences (PNAS).

Davis says the results show how intranasal foralumab has had similar immune gene expression effects in COVID patients, MS patients and in heathy volunteers that were included in the study. From this study, Davis adds that intranasal foralumab could have a wider opportunity as a treatment for other inflammatory human diseases.

Contact Details

Proactive US

+1 347-449-0879

This email address is being protected from spambots. You need JavaScript enabled to view it.